Related references
Note: Only part of the references are listed.Defining Tumor Rupture in Gastrointestinal Stromal Tumor
Toshirou Nishida et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine
T. Holmebakk et al.
BRITISH JOURNAL OF SURGERY (2016)
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial
Heikki Joensuu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Prospective Observational Study of Imatinib Therapy in Japanese Patients with Advanced Gastrointestinal Stromal Tumors: Long-term Follow-up and Second Malignancy
Tatsuo Kanda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
Heikki Joensuu et al.
LANCET ONCOLOGY (2012)
Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - The impact of tumour rupture on patient outcomes
P. Rutkowski et al.
EJSO (2011)
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P. DeMatteo et al.
LANCET (2009)
Risk stratification of patients diagnosed with gastrointestinal stromal tumor
Heikki Joensuu
HUMAN PATHOLOGY (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gastrointestinal stromal tumors: Pathology and prognosis at different sites
Markku Miettinen et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2006)
Diagnosis of gastrointestinal stromal tumors: A consensus approach
CDM Fletcher et al.
HUMAN PATHOLOGY (2002)